ProKidney Corp. (PROK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProKidney Corp. (PROK) has a cash flow conversion efficiency ratio of -0.108x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.51 Million) by net assets ($300.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of ProKidney Corp. to measure how much of total assets are equity-financed.
ProKidney Corp. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore ProKidney Corp. cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
ProKidney Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProKidney Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HMH Holding Inc. Class A Common Stock
NASDAQ:HMH
|
0.010x |
|
Yatsen Holding
NYSE:YSG
|
-0.033x |
|
Indoco Remedies Limited
NSE:INDOCO
|
0.169x |
|
SOHO China Limited
F:45S
|
0.005x |
|
MacroGenics Inc
NASDAQ:MGNX
|
0.774x |
|
Lealea Enterprise Co Ltd
TW:1444
|
0.003x |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
N/A |
|
TFE Co. Ltd.
KQ:425420
|
0.015x |
Annual Cash Flow Conversion Efficiency for ProKidney Corp. (2019–2025)
The table below shows the annual cash flow conversion efficiency of ProKidney Corp. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see ProKidney Corp. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $300.79 Million | $-120.12 Million | -0.399x | -26.94% |
| 2024-12-31 | $401.64 Million | $-126.35 Million | -0.315x | -36.68% |
| 2023-12-31 | $391.34 Million | $-90.07 Million | -0.230x | -50.76% |
| 2022-12-31 | $504.94 Million | $-77.09 Million | -0.153x | +91.83% |
| 2021-12-31 | $26.92 Million | $-50.30 Million | -1.869x | +26.80% |
| 2020-12-31 | $9.86 Million | $-25.18 Million | -2.553x | -52690.69% |
| 2019-12-31 | $15.88 Million | $-76.81K | -0.005x | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more